Oncological Outcomes After Multidisciplinary Management of Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL).
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL)
Breast implants
Capsulectomy
Lymphoma
Non-Hodgkin lymphoma
Journal
Annals of surgical oncology
ISSN: 1534-4681
Titre abrégé: Ann Surg Oncol
Pays: United States
ID NLM: 9420840
Informations de publication
Date de publication:
Oct 2023
Oct 2023
Historique:
received:
04
05
2023
accepted:
19
06
2023
medline:
12
9
2023
pubmed:
16
7
2023
entrez:
15
7
2023
Statut:
ppublish
Résumé
Breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) is an uncommon type of non-Hodgkin lymphoma, associated with breast implant capsules. Despite improvements in our understanding of BIA-ALCL, communicating the prognosis to patients remains challenging due to limited long-term follow-up data. This has important implications for decision-making, including recommendations for subsequent reconstructive procedures. The aim of this study was to assess the longer-term oncological outcomes of patients receiving multidisciplinary treatment for BIA-ALCL. This was a retrospective cohort study of BIA-ALCL patients treated at a tertiary referral unit. The data are presented using simple descriptive statistics. Between 2015 and 2022, 18 BIA-ALCL patients were treated at our institution. The median age at diagnosis was 48.5 (IQR 41-55) years. Ten patients developed BIA-ALCL after cosmetic breast augmentation, and 8 after breast reconstruction following mastectomy for cancer. All patients had a history of textured implant insertion. The median time from first implant surgery to diagnosis was 8.5 (IQR 7-12) years. All patients underwent en-bloc total capsulectomy with implant removal, and 2 received systemic therapy. Fifteen patients had Stage I (IA-IC) disease, 2 had Stage IIA and 1 Stage III BIA-ALCL, based on the TNM classification system. At a median follow-up of 45 (IQR 15-71) months, there were no episodes of local or systemic relapse or death. Surgical management for BIA-ALCL is sufficient in early-stage disease, and associated with excellent oncological outcomes. This information is reassuring for patients when discussing recurrence risk.
Identifiants
pubmed: 37454017
doi: 10.1245/s10434-023-13889-3
pii: 10.1245/s10434-023-13889-3
doi:
Types de publication
Journal Article
Langues
eng
Sous-ensembles de citation
IM
Pagination
6170-6175Informations de copyright
© 2023. Society of Surgical Oncology.
Références
Keech JA Jr, Creech BJ. Anaplastic T-cell lymphoma in proximity to a saline-filled breast implant. Plast Reconstr Surg. 1997;100(2):554–5.
doi: 10.1097/00006534-199708000-00065
pubmed: 9252643
Swerdlow SH, Campo E, Pileri SA, Harris NL, Stein H, Siebert R, et al. The 2016 Revision of the World Health Organization classification of lymphoid neoplasms. Blood. 2016;127(20):2375–90.
doi: 10.1182/blood-2016-01-643569
pubmed: 26980727
pmcid: 4874220
Sharma K, Gilmour A, Jones G, O’Donoghue JM, Clemens MW. A Systematic review of outcomes following breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). JPRAS Open. 2022;34:178–88.
doi: 10.1016/j.jpra.2022.08.008
pubmed: 36340855
pmcid: 9634150
Miranda RN, Aladily TN, Prince HM, Kanagal-Shamanna R, de Jong D, Fayad LE, et al. Breast implant-associated anaplastic large-cell lymphoma: long-term follow-up of 60 patients. J Clin Oncol. 2014;32(2):114–20.
doi: 10.1200/JCO.2013.52.7911
pubmed: 24323027
Clemens MW, Medeiros LJ, Butler CE, Hunt KK, Fanale MA, Horwitz S, et al. Complete surgical excision is essential for the management of patients with breast implant-associated anaplastic large-cell lymphoma. J Clin Oncol. 2016;34(2):160–8.
doi: 10.1200/JCO.2015.63.3412
pubmed: 26628470
Turton P, El-Sharkawi D, Lyburn I, Sharma B, Mahalingam P, Turner SD, et al. UK guidelines on the diagnosis and treatment of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL) on behalf of the medicines and healthcare products regulatory agency (MHRA) plastic, reconstructive and aesthetic surgery expert advisory group (PRASEAG). Eur J Surg Oncol. 2021;47(2):199–210.
doi: 10.1016/j.ejso.2020.07.043
pubmed: 33358076
Santanelli di Pompeo F, Sorotos M, Clemens MW, Firmani G, Safety EAoPSCoD, Development. Breast Implant-Associated Anaplastic Large Cell Lymphoma (BIA-ALCL): Review of Epidemiology and Prevalence Assessment in Europe. Aesthet Surg J. 2020;41(9):1014–25.
Cordeiro PG, Ghione P, Ni A, Hu Q, Ganesan N, Galasso N, et al. Risk of breast implant associated anaplastic large cell lymphoma (BIA-ALCL) in a cohort of 3546 women prospectively followed long term after reconstruction with textured breast implants. J Plastic Reconstruct Aesthet Surg. 2020;73(5):841–6.
doi: 10.1016/j.bjps.2019.11.064
de Boer M, van Leeuwen FE, Hauptmann M, Overbeek LIH, de Boer JP, Hijmering NJ, et al. Breast implants and the risk of anaplastic large-cell lymphoma in the breast. JAMA Oncol. 2018;4(3):335–41.
doi: 10.1001/jamaoncol.2017.4510
pubmed: 29302687
pmcid: 5885827
Doren EL, Miranda RN, Selber JC, Garvey PB, Liu J, Medeiros LJ, et al. U.S. Epidemiology of Breast Implant-Associated Anaplastic Large Cell Lymphoma. Plast Reconstr Surg. 2017;139(5):1042–50.
Collett DJ, Rakhorst H, Lennox P, Magnusson M, Cooter R, Deva AK. Current Risk Estimate of Breast Implant-Associated Anaplastic Large Cell Lymphoma in Textured Breast Implants. Plast Reconstr Surg. 2019;143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma):30S–40S.
De Jong WH, Panagiotakos D, Proykova A, Samaras T, Clemens MW, De Jong D, et al. Final opinion on the safety of breast implants in relation to anaplastic large cell lymphoma: Report of the scientific committee on health, emerging and environmental risks (SCHEER). Regul Toxicol Pharmacol: RTP. 2021;125:104982.
doi: 10.1016/j.yrtph.2021.104982
pubmed: 34214611
Lajevardi SS, Rastogi P, Isacson D, Deva AK. What are the likely causes of breast implant associated anaplastic large cell lymphoma (BIA-ALCL)? JPRAS Open. 2022;32:34–42.
doi: 10.1016/j.jpra.2021.11.006
pubmed: 35242986
pmcid: 8867047
Ionescu P, Vibert F, Amé S, Mathelin C. New data on the epidemiology of breast implant-associated anaplastic large cell lymphoma. Eur J Breast Health. 2021;17(4):302–7.
doi: 10.4274/ejbh.galenos.2021.2021-5-6
pubmed: 34651107
pmcid: 8496114
Oishi N, Miranda RN, Feldman AL. Genetics of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Aesthet Surg J. 2019;39(Supplement_1):S14-S20.
Adlard J, Burton C, Turton P. Increasing evidence for the association of breast implant-associated anaplastic large cell lymphoma and Li Fraumeni syndrome. Case Rep Genet. 2019;2019:5647940.
pubmed: 31392066
pmcid: 6662482
Hallab NJ, Samelko L, Hammond D. The inflammatory effects of breast implant particulate shedding: comparison with orthopedic implants. Aesthet Surg J. 2019;39(Supplement_1):S36-S48.
Giot JP, Paek LS, Nizard N, El-Diwany M, Gaboury LA, Nelea M, et al. The double capsules in macro-textured breast implants. Biomaterials. 2015;67:65–72.
doi: 10.1016/j.biomaterials.2015.06.010
pubmed: 26210173
Turner SD. The cellular origins of breast implant–associated anaplastic large cell lymphoma (BIA-ALCL): implications for immunogenesis. Aesthet Surg J. 2019;39(Supplement_1):S21-S7.
Kadin ME. What cytokines can tell us about the pathogenesis of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Aesthet Surg J. 2019;39(Supplement_1):S28–35.
Rondón-Lagos M, Rangel N, Camargo-Villalba G, Forero-Castro M. Biological and genetic landscape of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Eur J Surg Oncol. 2021;47(5):942–51.
doi: 10.1016/j.ejso.2020.10.029
pubmed: 33158639
Clemens MW, Jacobsen ED, Horwitz SM. 2019 NCCN consensus guidelines on the diagnosis and treatment of breast implant-associated anaplastic large cell lymphoma (BIA-ALCL). Aesthet Surg J. 2019;39(Suppl_1):S3-S13.
Santanelli di Pompeo F, Clemens MW, Atlan M, Botti G, Cordeiro PG, De Jong D, et al. 2022 Practice recommendation updates from the world consensus conference on BIA-ALCL. Aesthet Surg J. 2022;42(11):1262-78.
Laurent C, Delas A, Gaulard P, Haioun C, Moreau A, Xerri L, et al. Breast implant-associated anaplastic large cell lymphoma: two distinct clinicopathological variants with different outcomes. Ann Oncol. 2016;27(2):306–14.
doi: 10.1093/annonc/mdv575
pubmed: 26598546
Tevis SE, Hunt KK, Miranda RN, Lange C, Pinnix CC, Iyer S, et al. Breast Implant-associated anaplastic large cell lymphoma: a prospective series of 52 patients. Ann Surg. 2022;275(1):e245–9.
doi: 10.1097/SLA.0000000000004035
pubmed: 32568749
Lillemoe HA, Miranda RN, Nastoupil LJ, Clemens MW, Hunt KK. Clinical manifestations and surgical management of breast implant-associated anaplastic large cell lymphoma: beyond the NCCN guidelines. Ann Surg Oncol. 2022;29(9):5722–9.
doi: 10.1245/s10434-022-11838-0
pubmed: 35597841
Lamaris GA, Butler CE, Deva AK, Miranda RN, Hunt KK, Connell T, et al. Breast Reconstruction Following Breast Implant-Associated Anaplastic Large Cell Lymphoma. Plast Reconstr Surg. 2019;143(3S A Review of Breast Implant-Associated Anaplastic Large Cell Lymphoma):51S-8S.
Lee WS, Kim TG, Lee JH, Kim IK. Breast reconstruction after breast implant-associated anaplastic large cell lymphoma treatment: a case report and literature review. J Clin Med. 2023;12(5).
Longo B, Di Napoli A, Curigliano G, Veronesi P, Pileri S, Martelli M, et al. Clinical recommendations for diagnosis and treatment according to current updated knowledge on BIA-ALCL. Breast (Edinburgh, Scotland). 2022;66:332–41.
doi: 10.1016/j.breast.2022.11.009
pubmed: 36502569
pmcid: 9763507